Abstract:The MYC oncogene encodes for the MYC protein and is frequently dysregulated across multiple cancer cell types, making it an attractive target for cancer therapy. MYC overexpression leads to MYC binding at active enhancers, resulting in a global transcriptional amplification of active genes. Because super-enhancers are frequently dysregulated in cancer, we hypothesized that MYC preferentially invades into super-enhancers and alters the cancer genome organization. To that end, we performed ChIP-seq, RNA-seq, circular chromosome conformation capture (4C-seq), and Spike-in Quantitative Hi-C (SIQHiC) on the U2OS osteosarcoma cell line with tetracycline-inducible MYC . MYC overexpression in U2OS cells modulated histone acetylation and increased MYC binding at super-enhancers. SIQHiC analysis revealed increased global chromatin contact frequency, particularly at chromatin interactions connecting MYC binding sites at promoters and enhancers. Immunofluorescence staining showed that MYC molecules formed punctate foci at these transcriptionally active domains after MYC overexpression. These results demonstrate the accumulation of overexpressed MYC at promoter–enhancer hubs and suggest that MYC invades into enhancers through spatial proximity. At the same time, the increased protein–protein interactions may strengthen these chromatin interactions to increase chromatin contact frequency. CTCF siRNA knockdown in MYC -overexpressed U2OS cells demonstrated that removal of architectural proteins can disperse MYC and abrogate the increase in chromatin contacts. By elucidating the chromatin landscape of MYC-driven cancers, we can potentially target MYC-associated chromatin interactions for cancer therapy.

Insights into the Links between MYC and 3D Chromatin Structure and Epigenetics Regulation: Implications for Cancer Therapy

Transcriptional regulation by MYC: an emerging new model

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

Exploring Myc puzzle: Insights into cancer, stem cell biology, and PPI networks

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

MYC protein interactors in gene transcription and cancer

MYC on the Path to Cancer

MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis

MYC: there is more to it than cancer

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer.

MYC reshapes CTCF-mediated chromatin architecture in prostate cancer

Targeting MYC at the intersection between cancer metabolism and oncoimmunology

Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat

Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

3D chromatin architecture and transcription regulation in cancer

The role of c-Myc in Epstein-Barr virus-associated cancers: Mechanistic insights and therapeutic implications

MYC in Liver Cancer: Mechanisms and Targeted Therapy Opportunities

Genetic and Epigenetic Dysregulation of Transcriptional Enhancers in Cancer

MYC dysfunction modulates stemness and tumorigenesis in breast cancer

Target gene-independent functions of MYC oncoproteins